Long-term management of generalized pustular psoriasis with infliximab: Case series

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 4, 2008, Pages 184-188

  Routhouska, Shannon B ^a   Sheth, Pranav B ^a   Korman, Neil J ^a,b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CALCIPOTRIOL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DAPSONE; DIPHENHYDRAMINE; ETANERCEPT; ETRETIN; ETRETINATE; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; HYDROCORTISONE; INFLIXIMAB; ISOTRETINOIN; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; PARACETAMOL; PIMECROLIMUS; PSORALEN; TIOGUANINE; TRIAMCINOLONE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CASE REPORT; CASE STUDY; CAUCASIAN; CELLULITIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INFUSION; DRUG WITHDRAWAL; DYSPNEA; EXTERNAL OTITIS; FEMALE; FOLLOW UP; HERPES SIMPLEX; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; LONG TERM CARE; MONOTHERAPY; OTITIS MEDIA; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; PUVA; SKIN TOXICITY; TACHYCARDIA; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; METHOTREXATE; PSORIASIS;

EID: 51349119641     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07036     Document Type: Article

References (32)

1. Baker H, Ryan T. Generalized pustular psoriasis: a clinical and epidemiological study of 104 cases. Br J Dermatol 1968;80:771-93.
2. Prystowski J, Cohen P. Pustular and erythrodermic psoriasis. Dermatol Clin 1995;13:757-70.
3. Lebwohl M. Psoriasis. Lancet 2003;361:1197-204.
4. Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47:796-7.
5. Newland MR, Weinnstein A. Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-52.
6. Barland C. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol 2003;139:949-50.
7. Benoit S, Toksoy A, Brocker EB, et al. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 2004;150:1009-12.
8. Schmick K, Grabbe J. Recalcitrant generalized pustular psoriasis: rapid and lasting therapeutic response to antitumor necrosis factor-α antibody (infliximab), Br J Dermatol, 2004;150:367.
9. Lisby S, Gniadecki R. Infliximab (remicade) for acute, severe pustular and erythrodermic psoriasis. Acta Derm Venerol 2004;86: 247-8.
10. Trent J, Kerdel F. Successful treatment of von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg 2004;8:224-8.
11. Cauhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab montherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
12. Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumor necrosis factor alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51.
13. Seishima M, Seishima M, Takemura M, et al. Increased serum soluble Fas, tumor necrosis factor α and interleukin 6 concentrations in generalized pustular psoriasis. Dermatology 1998;196:371-2.
14. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
15. Hanauer S, Feagan B, Lichtenstein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-9.
16. Kirby B, Marsland A, Carmichael A, et al. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clinc Exp Dermatol 2001;26:27-9.
17. Goedkoop A, Kraan M, Picavet D, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-center study. Arthritis Res Ther 2004;6:R326-34.
18. Maini R, Breedveld F, Kalden J, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
19. Lipsky P, van der Heijde D, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
20. Bens G, Laharie D, Beylot-Barry M, et al. Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. Br J Dermatol 2003;149:181-4.
21. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther 2004;19: 295-301.
22. Menter A, Feldman S, Weinstein G, et al. A. randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1-e15.
23. Wasserman M, Weber D, Suthrie J, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment and infusion number. J Rheumatol 2004;31:1912-7.
24. Lequerré T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from a immunotherapy unit of rheumatology. J Rheumatol 2006;33:1-8.
25. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-51.
26. Kramer N, Chuzhin Y, Kaufman L, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:670-1.
27. True D, Penmetcha M, Peckham S. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002;29:1561-3.
28. Courtney P, Alderdice J, Whitehead E. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. Arthritis Rheum 2003;49:617.
29. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7.
30. van der Klooster J, Bosman R, Oudemans-van Straaten H, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003;29:2327-9.
31. Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with sero-positive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. Ann Rheum Dis 2005;64:1098-9.
32. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006;33:1189-93.